PROTEOMIC BIOMARKERS IN SERUM OF THE THYROID CANCER PATIENTS

甲状腺癌患者血清中的蛋白质组生物标志物

• 批准号: 7959899
• 负责人: ELZBIETA Iwona ZAKRZEWSKA
• 金额: $ 0.34万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7959899
• 关键词: Aliquot; Biological Markers; Blood; Breast; Cancer Detection; Cancer Patient; Collection; Colorectal; Complex Mixtures; Computer Retrieval of Information on Scientific Projects Database; Computer Simulation; Development; Diagnosis; Disease; Experimental Designs; Fine needle aspiration biopsy; Foundations; Fractionation; Funding; Future; Genetic; Grant; Institution; Liver; Lung; Malignant Neoplasms; Malignant neoplasm of brain; Malignant neoplasm of thyroid; Mass Spectrum Analysis; Methods; Ovarian; Pancreas; Patients; Peptides; Plasma; Procedures; Process; Prostate; Protein Analysis; Proteins; Proteomics; Protocols documentation; Research; Research Personnel; Resources; Sampling; Screening procedure; Serum; Source; Techniques; Technology; Thyroid Nodule; Time; Tube; United States National Institutes of Health; Variant; Venipunctures; Vermont; novel; surface enhanced laser desorption ionization; Aliquot; Biological Markers; Blood; Breast; Cancer Detection; Cancer Patient; Collection; Colorectal; Complex Mixtures; Computer Retrieval of Information on Scientific Projects Database; Computer Simulation; Development; Diagnosis; Disease; Experimental Designs; Fine needle aspiration biopsy; Foundations; Fractionation; Funding; Future; Genetic; Grant; Institution; Liver; Lung; Malignant Neoplasms; Malignant neoplasm of brain; Malignant neoplasm of thyroid; Mass Spectrum Analysis; Methods; Ovarian; Pancreas; Patients; Peptides; Plasma; Procedures; Process; Prostate; Protein Analysis; Proteins; Proteomics; Protocols documentation; Research; Research Personnel; Resources; Sampling; Screening procedure; Serum; Source; Techniques; Technology; Thyroid Nodule; Time; Tube; United States National Institutes of Health; Variant; Venipunctures; Vermont; novel; surface enhanced laser desorption ionization

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The long term purpose of the project is to identify and explore a set of proteomic biomarkers specific to the type of thyroid cancer using blood serum. The immediate objective of this study is to establish standard protocols and procedures for the reproducible analysis of proteins from blood serum that could be used in biomarkers discovery not only in the thyroid cancer, but also other cancers and diseases. Therefore, the specific aim is to develop standard protocols and procedures for serum fractionation prior to SELDI analysis and to optimize SELDI-TOF analysis conditions. The proteomic profiles generated from these studies will be used for the development of computational models and provide the foundation for future experimental designs. Advances in the proteomics study opened more possibilities for less invasive cancer detection methods and for novel cancer biomarkers screening techniques. Surface-Enhanced Laser Desorption/Ionization  Time of Flight mass spectrometry (SELDI-TOF) and ProteinChip technology (BioRad, USA) offer a fast and sensitive method of analysis of a complex mixture of proteins and peptides. Recently SELDI-TOF has been successfully used to identify potential biomarkers for the diagnosis of ovarian, prostate, colorectal, breast, lung, pancreatic, liver, and brain cancers. We plan to collect 80 blood serum samples from patients diagnosed with thyroid nodule and referred for Fine Needle Aspiration procedure, however only a subset of 20 will be used initially to establish protocols. Samples are collected by venipuncture, and the blood is drawn according to the standardized protocols into serum and plasma collection tubes. Serum and plasma are aliquoted and stored immediately in -80C. Serum and plasma samples will be processed in batches to avoid variations in the processing. Up to this day we have collected samples from 8 patients only.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 该项目的长期目的是使用血清识别和探索一组针对甲状腺癌类型的蛋白质组学生物标志物。这项研究的直接目的是建立标准方案和程序，用于对血清中蛋白质的可再现分析，这不仅在甲状腺癌中，而且还可以用于生物标志物中，而且还可以在甲状腺癌中发现。因此，具体的目的是在SELDI分析之前制定标准方案和过程，以进行血清分级分级，并优化SELDI-TOF分析条件。这些研究产生的蛋白质组学特征将用于开发计算模型，并为将来的实验设计奠定了基础。 蛋白质组学研究的进步为减少侵入性癌症检测方法和新型癌症生物标志物筛查技术开辟了更多可能性。飞行质谱法（SELDI-TOF）和蛋白质奇普技术（美国Biorad）的表面增强激光解吸/电离时间提供了一种快速且敏感的方法，可以分析蛋白质和肽的复杂混合物。最近，Seldi-ToF已成功用于鉴定潜在的生物标志物，以诊断卵巢，前列腺，结直肠骨，乳房，肺，胰腺，胰腺，肝脏和脑部癌。 我们计划从诊断为甲状腺结节的患者中收集80种血清样本并转介进行细针吸入程序，但是最初仅使用20个子集来建立方案。 样品是通过静脉穿刺收集的，并根据标准化方案抽取血液和血浆收集管。血清和血浆是等分的，并立即以-80C的形式储存。血清和血浆样品将分批处理，以避免处理中的变化。 直到今天，我们仅收集了8例患者的样品。